Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naïve and -Experienced Patients Infected With B and Non-B HIV-1 Variants
作者： Carolina Gutiérrez , Beatriz Hernández-Novoa , María Jesús Pérez-Elías , Ana María Moreno , África Holguín
DOI: 10.1310/HCT1401-10
关键词:
摘要: AbstractBackground: Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) in clinical practice. Three independent pathways have been described to confer resistance RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions an uncertain role also especially HIV-1 non-B variants. Methods: We evaluated prevalence of primary, secondary, INSTIs patients naive RAL or elvitegravir (EGV) carrying different Results: A total 83 infected by B subtype (64%) variants (36%) were evaluated. No primary EGV found inte-grase sequences analyzed. detected only 5 patients. Additional both According geno2pheno algorithm, some secondary (L74V, E138K, G163RS, V151I) b...
sci-hub.se 参考文章(44)
Michael J. Kozal, Max Lataillade, Jennifer Chiarella, Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antiviral Therapy. ,vol. 12, pp. 563- 570 ,(2007)
Antonio Piralla, Stefania Paolucci, Roberto Gulminetti, Giuditta Comolli, Fausto Baldanti, HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients. Virology Journal. ,vol. 8, pp. 149- 149 ,(2011) , 10.1186/1743-422X-8-149
Benjamin Young, Signe Fransen, Kenneth S Greenberg, Amy Thomas, Sharon Martens, Marty St Clair, Christos J Petropoulos, Belinda Ha, Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antiviral Therapy. ,vol. 16, pp. 253- 256 ,(2011) , 10.3851/IMP1748
Kurt Van Baelen, Veerle Van Eygen, Evelien Rondelez, Lieven J Stuyver, Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS. ,vol. 22, pp. 1877- 1880 ,(2008) , 10.1097/QAD.0B013E32830F9703
Ombretta Turriziani, Claudia Montagna, Francesca Falasca, Mauro Bucci, Gianluca Russo, Miriam Lichtner, Martin Sanou Sobze, Vincenzo Vullo, Mauro Pistello, Guido Antonelli, Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon. AIDS Research and Human Retroviruses. ,vol. 28, pp. 1729- 1733 ,(2012) , 10.1089/AID.2011.0266
David A Cooper, Roy T Steigbigel, Jose M Gatell, Jurgen K Rockstroh, Christine Katlama, Patrick Yeni, Adriano Lazzarin, Bonaventura Clotet, Princy N Kumar, Joseph E Eron, Mauro Schechter, Martin Markowitz, Mona R Loutfy, Jeffrey L Lennox, Jing Zhao, Joshua Chen, Desmond M Ryan, Rand R Rhodes, John A Killar, Lucinda R Gilde, Kim M Strohmaier, Anne R Meibohm, Michael D Miller, Daria J Hazuda, Michael L Nessly, Mark J DiNubile, Robin D Isaacs, Hedy Teppler, Bach-Yen Nguyen, None, Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. The New England Journal of Medicine. ,vol. 359, pp. 355- 365 ,(2008) , 10.1056/NEJMOA0708978
Jeffrey L Lennox, Edwin DeJesus, Daniel S Berger, Adriano Lazzarin, Richard B Pollard, Jose Valdez Ramalho Madruga, Jing Zhao, Hong Wan, Christopher L Gilbert, Hedy Teppler, Anthony J Rodgers, Richard JO Barnard, Michael D Miller, Mark J DiNubile, Bach-Yen Nguyen, Randi Leavitt, Peter Sklar, STARTMRK Investigators, None, Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses Journal of Acquired Immune Deficiency Syndromes. ,vol. 55, pp. 39- 48 ,(2010) , 10.1097/QAI.0B013E3181DA1287
Jean-Michel Molina, Anthony LaMarca, Jaime Andrade-Villanueva, Bonaventura Clotet, Nathan Clumeck, Ya-Pei Liu, Lijie Zhong, Nicolas Margot, Andrew K Cheng, Steven L Chuck, Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study Lancet Infectious Diseases. ,vol. 12, pp. 27- 35 ,(2012) , 10.1016/S1473-3099(11)70249-3
Saarah Arshad, Michael Rothberg, Darius A Rastegar, Linda M Spooner, Daniel Skiest, Survey of physician knowledge regarding antiretroviral medications in hospitalized HIV-infected patients Journal of the International AIDS Society. ,vol. 12, pp. 1- 10 ,(2009) , 10.1186/1758-2652-12-1
Sarita D Boyd, Frank Maldarelli, Irini Sereti, G Laissa Ouedraogo, Catherine A Rehm, Valerie Boltz, Diana Shoemaker, Alice K Pau, Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antiviral Therapy. ,vol. 16, pp. 257- 261 ,(2011) , 10.3851/IMP1749